Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

Last updated: September 26, 2023
Sponsor: Glaukos Corporation
Overall Status: Active - Recruiting

Phase

N/A

Condition

Glaucoma

Treatment

iStent Infinite

Clinical Study ID

NCT06057051
GLK-401-01
  • Ages > 35
  • All Genders

Study Summary

Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of primary open-angle glaucoma
  • Phakic or pseudophakic
  • Age 35 years or older

Exclusion

Exclusion Criteria:

  • Traumatic, uveitic, neovascular, angle-closure glaucoma or
  • glaucoma associated with vascular disorders
  • Active corneal inflammation or edema
  • Retinal disorders not associated with glaucoma

Study Design

Total Participants: 245
Treatment Group(s): 1
Primary Treatment: iStent Infinite
Phase:
Study Start date:
September 01, 2023
Estimated Completion Date:
August 31, 2027

Connect with a study center

  • Glaukos Investigator Site

    Cincinnati, Ohio 45242
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.